| Id |
Subject |
Object |
Predicate |
Lexical cue |
| T646 |
0-276 |
Sentence |
denotes |
The efficacy and safety of thalidomide in the adjuvant treatment of moderate new coronavirus (COVID‐19) pneumonia Drug: thalidomide, placebo COVID‐19 thalidomide 100, all, 18 years and older Treatment Placebo comparator: control group: placebo 100 mg, po, qn, for 14 days |
| T647 |
277-337 |
Sentence |
denotes |
Experimental: thalidomide group 100 mg, po, qn, for 14 days. |
| T648 |
338-459 |
Sentence |
denotes |
Other name: fanyingting II Primary (up to 28 days): time to clinical recovery time to clinical recovery (up to 28 days) |
| T649 |
460-583 |
Sentence |
denotes |
Secondary (up to 28 days): all cause mortality (up to 28 days), frequency of respiratory progression, Time to defervescence |
| T650 |
584-1222 |
Sentence |
denotes |
Others(up to 28 days): time to cough reported as mild or absent, respiratory improvement time, frequency of requirement for supplemental oxygen or noninvasive ventilation, Time to 2019‐nCoV RT‐PCR negative in upper respiratory tract specimen, change (reduction) in 2019‐nCoV viral load in upper respiratory tract specimen as assessed by area under viral load curve, frequency of requirement for mechanical ventilation, frequency of serious adverse events, Serum TNF‐α, IL‐1β, IL‐2, IL‐6, IL‐7, IL‐10, GSCF, IP10, MCP1, MIP1α and other cytokine expression levels before and after treatment NCT04273529/Not yet recruiting, Feb20‐Jun30 2020 |
